Further trial for Anika's Orthovisc underway in US:
This article was originally published in Clinica
Executive Summary
Anika Therapeutics has begun a further a Phase III clinical trial of its treatment for osteoarthritic knees, under an investigational device exemption from the US FDA. The Woburn, Massachusetts-based company failed to win US approval for the product last year due to insufficient data from its initial study. Orthovisc, an injectable hyaluronic acid-based product for restoring the elasticity and viscosity of synovial fluid, will be evaluated in around 350 patients at 20 sites in both Canada and the US.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.